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Cytokine and Chemokine 
Concentrations as Biomarkers of 
Feline Mycobacteriosis
C. O’Halloran  1, L. McCulloch2, L. Rentoul3, J. Alexander4, J. C. Hope  1 & D. A. Gunn-Moore1
Mycobacteriosis is an emerging zoonotic disease of domestic cats and timely, accurate diagnosis is 
currently challenging. To identify differential cytokine/chemokine concentrations in serum/plasma 
of cats, which could be diagnostic biomarkers of infection we analysed plasma/serum from 116 
mycobacteria-infected cats, 16 healthy controls and six cats hospitalised for unrelated reasons was 
analysed using the Milliplex MAP Feline Cytokine Magnetic Bead multiplex assay. Three cytokines; 
sFAS, IL-13 and IL-4 were reduced while seven; GM-CSF, IL-2, PDGF-BB, IL-8, KC, RANTES and TNF-α 
were elevated in mycobacteria-infected cats compared to healthy controls. However, IL-8 and KC 
concentrations were not significantly different from cats hospitalised for other reasons. Elevations in 
TNF-α and PDGF-BB may have potential to identify M. bovis and M. microti infected cats specifically 
while GM-CSF, IL-2 and FLT3L were increased in MTBC infected cats. This study demonstrates 
potential use of feline tuberculosis as a spontaneously occurring model of this significant human 
disease. Cytokine profiling has clear diagnostic potential for mycobacteriosis of cats and could be used 
discriminate tuberculous from non-tuberculous disease to rapidly inform on zoonotic risk. Future work 
should focus on the in-field utility of these findings to establish diagnostic sensitivity and specificity of 
these markers.
Tuberculosis (TB) has been the cause of considerable morbidity and mortality in the human population for cen-
turies, and remains the leading cause of death from any single infectious agent (Mycobacterium (M.) tubercu-
losis) worldwide1–3. Historically, the significance of this disease has resulted in extensive biomedical research 
interest and, due to the growing threat of drug resistance, TB is a major focus of collaborative global healthcare 
investment4–8. Meanwhile, TB in domestic cats receives relatively little research attention, despite being more 
common and clinically significant than previously thought9–11. In the UK, approximately 1% of all feline biopsies 
submitted for routine histopathological analysis show changes consistent with mycobacteriosis and a third of 
these contain Ziehl-Neelsen (ZN) positive organisms when stained, with morphology indicative of the presence 
of mycobacteria10,12.
The various mycobacterial species that have been identified in companion animals, including cats, 
can be grouped into the same two major categories as human mycobacterial disease; those belonging to the 
Mycobacterium tuberculosis-complex (MTBC) and the non-tuberculous mycobacteria (NTM, also referred to as 
‘atypical mycobacteria’ or ‘mycobacteria other than tuberculosis’, MOTT)11,13–19.
The MTBC consists of ten highly genetically related species of mycobacteria which are capable of causing TB 
in both man and other animals, and are some of the oldest recorded zoonotic diseases known to both human and 
veterinary medicine20–26. All member species of the complex share identical sequences across the 16s rRNA gene 
and 99.5% sequence homology across the remainder of the genome27. The most discriminating features between 
the species at the nucleotide level are genomic deletions, termed regions of difference (RD)28–31. The MTBC 
organisms which infect cats, Mycobacterium microti and Mycobacterium bovis, differ by RD112,32–34. This region 
is absent from M. microti but present in all other MTBC organisms28. It has been shown to encode a variety of 
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molecules which act as virulence factors which are also immuno-dominant proteins such as; early secreted anti-
genic target-6KDa (ESAT-6) and culture filtrate protein-10KDa (CFP-10)35–37.
In companion animals, such as cats, MTBC infections pose a potential zoonotic risk to their owners; addition-
ally these cases may act as a potential source of environmental contamination with mycobacteria such as M. bovis, 
a pathogen of major animal health significance in the UK and other countries as the causative agent of bovine 
tuberculosis (bTB)38–41.
In stark contrast to human TB cases, the majority of feline TB cases present with localised nodular cutaneous 
disease, frequently with a degree of ulceration and occasionally with a draining sinus tract9,13,14,34. The lesions are 
typically distributed around the face, extremities and tail base – the so-called “fight and bite sites”15,34. Skin lesions 
may be accompanied by a localised or even generalised lymphadenopathy, or lymphadenopathy (usually of the 
submandibular, pre-scapular or popliteal nodes) may be the only presenting sign, termed an incomplete primary 
complex14,33,34.
Pulmonary lesions do occur in cats, but rarely result from bacteria being inhaled and causing typical tubercle 
formation in the lungs and hilar lymph nodes9,14. Much more commonly, pulmonary disease is secondary to the 
putative haematogenous spread of bacteria from the site of inoculation in the skin12,14. This generates a diffuse 
interstitial pattern of disease which eventually becomes bronchial and is clinically observable as progressive dysp-
noea followed eventually by a soft productive cough14,34. Radiographically this presents differently from primary 
pulmonary infection which more frequently causes the “classical” tuberculous cavitating lesions34. Disseminated 
disease can cause a range of clinical signs including hepato-splenomegaly, pleural and pericardial effusions, gen-
eralised lymphadenopathy, weight loss and pyrexia9,13,16,33,34.
With such variable clinical presentation and non-specific clinical signs, diagnosing feline mycobacterial infec-
tions rapidly and accurately is challenging. Mycobacterial culture conducted by the Animal and Plant Health 
Agency (APHA), is currently the recognised ‘gold standard test’ for the diagnosis of mycobacterial disease in UK 
companion animals; however, it has several limiting features. Firstly, it has been shown to have a relatively poor 
sensitivity of ~50%, secondly it requires weeks from the time that a contaminated tissue biopsy is submitted for 
results to be obtained e.g. the average culture time is 12–16 weeks for M. microti - the most frequently cultured 
organism9,34,42. During this time, if untreated, a patient will remain a potential source of infection to both its 
owner and the local environment.
As such, alternative diagnostic tests have been developed which aim to reduce the amount of time between 
clinical presentation and a definitive diagnosis being reached. Interferon-gamma (IFN-γ) release assays (IGRA) 
were developed on the principle of quantitatively evaluating IFN-γ production by peripherally circulating 
antigen-specific effector T-memory cells upon in vitro stimulation, in order to aid the diagnosis of bTB in cat-
tle43–46. These have subsequently been adapted to identify both active and latent TB in human patients with both 
greater sensitivity and specificity than the previously utilised tuberculin skin test47–49. Where intra-dermal testing 
has been shown to be of unreliable clinical utility in the cat, the IGRA has been used successfully14,45.
IGRAs have several advantages over other diagnostic techniques; they are significantly quicker at generating 
results than culture and are cheaper than many commercially available PCR and subsequent sequencing methods, 
they are also relatively non-invasive requiring only a single peripheral blood sample45,48. Unlike intra-dermal 
skin testing, they can be repeated if necessary as conducting the assay does not alter the systemic immune 
response44,50,51. In 2008, an adapted methodology of the IGRA was validated for diagnostic use in cats; this assay 
has a reported 100% sensitivity to indicate MTBC infection45.
Recently, within the field of human diagnostics of mycobacterial diseases, and of TB in particular, there has 
been a marked increase in research focussed on the identification of circulating cytokine biomarkers for the diag-
nosis of both active and latent MTBC infections in humans52–57. The goal of such assays is to cheaply, sensitively 
and rapidly identify infected and infectious individuals, in order to combat what remains one of the most inci-
dent infectious diseases of man58. Such studies have utilised multiplex cytokine assays, most commonly Luminex 
xMAP technologies, with promising results54,59,60. Studies of multiple assays have found circulating cytokine con-
centrations and combinations of cytokines which can sensitively and specifically diagnose both active and latent 
TB in humans52–57. For example; CXCL10 and CCL2 plasma concentrations can be combined with circulating 
levels of IFN-γ to more accurately discriminate between active and latent TB states, whilst the quantification of 
vascular endothelial growth factor can help differentiate patients with TB pleural effusion from those with neo-
plastic pleural effusions57,61. Similar assays have also been used successfully in the study of a limited number of 
companion animal diseases, including canine lymphoma and feline cystitis62–65.
As the timely and accurate diagnosis of feline mycobacteriosis, and the identification of the causative spe-
cies is currently challenging, the aim of this study was to evaluate whether cytokine profiling from peripheral 
blood samples of infected cats demonstrated the same clinical utility as has been shown for humans. We there-
fore hypothesised that a number of cytokines would be differentially detectable in cats infected with mycobacte-
rial infections when compared to both healthy controls and sick cats hospitalised for other reasons. We further 
hypothesised that the cytokine response would differ according to the species of mycobacteria present in the 
patient.
Materials and Methods
Mycobacteria spp. infected cat blood sample collection. Blood samples analysed in this study con-
sisted of either heparinised plasma or separated serum. Archived remnant samples obtained opportunistically 
by vets and donated by the cats’ owners were used in this project. Cats diagnosed with mycobacterial infection 
by histological identification of (pyo)granulomatous inflammation in lesion biopsy material with the presence of 
acid-fast bacilli morphologically indicative of mycobacteria were considered eligible for inclusion in this study. 
Private veterinary surgeons who contacted the Royal (Dick) School of Veterinary Studies for clinical assistance 
with case management were asked to retain any blood samples remaining after diagnostic procedures had been 
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performed. With the owner’s consent, these samples were then sent directly to the University of Edinburgh where 
they were retained at −80 °C prior to analysis of chemokine and cytokine concentrations.
Cats were excluded from the study if, prior to blood sample collection, they had been known to be treated with 
immunomodulatory medications e.g. non-steroidal anti-inflammatories (NSAIDs), chemotherapeutic agents or 
corticosteroids within 14 days of sample collection. Cats were additionally excluded if they were pre-treated 
with antibiotics with efficacy against mycobacteria, including fluoroquinolones, macrolides/azides or doxycycline 
within the same time period. Cats were not excluded if they had been treated with antimicrobial agents if these 
would be ineffective against mycobacteria, such as a penicillin or cephalosporin. Similarly, cats were not excluded 
if they had been treated with non-immunomodulatory analgesic medications e.g. opioids.
This study was conducted following approval from the School of Veterinary Medicine Ethical Review 
Committee at the University of Edinburgh; all relevant guidelines and regulations were adhered to throughout.
Speciation of mycobacteria infecting case animals. All cats included in this study had positive histo-
logical diagnoses of mycobacterial infection as outlined above. Of these, cases which had undergone additional 
IGRA, PCR or culture testing were sub-classified by the species of infecting organism identified.
Cases were defined as being infected with an MTBC mycobacteria if the cat had an IGRA test which showed 
an antigen specific IFN-γ response biased to purified protein derivative from M. bovis (PPDB) above that gen-
erated in response to purified protein derivative from M. avium (PPDA). The MTBC cases which additionally 
responded to the ESAT-6/CFP-10 peptide combination were classified as M. bovis infected. Cats which did not 
respond to the ESAT-6/CFP-10 peptide cocktail but showed a PPDB biased response were defined as being 
infected with M. microti. Cats with a positive IGRA test that did not meet the criteria for MTBC infection were 
classified as being infected with non-tuberculous mycobacteria. Both the test method and interpretation have 
previously been described by Rhodes et al.45.
In addition to IGRA testing, the results of mycobacterial culture from tissue biopsies were used, where avail-
able, when conducted by APHA and/or PCR results were used to speciate infections when conducted by Leeds 
University Teaching Hospital Mycobacterial Reference Laboratory.
Collection of control cat blood samples. Remnant serum samples from healthy control cats were kindly 
gifted from the Waltham Centre for Pet Nutirtion. At the time of sampling each control animal underwent an 
annual routine health check comprising compete physical examination by the attending veterinary surgeon, plus 
full haematological testing and serum biochemical analyses. All cats were required to have findings for these 
tests within normal limits to be included as a control animal in this study. Separated serum were aliquoted, and 
sent directly to the University of Edinburgh and stored −80 °C prior to analysis of chemokine and cytokine 
concentrations.
Collection of hospitalised cat blood samples. Remnant serum was obtained from cats Hospital for 
Small Animals, at the Royal (Dick) School of Veterinary Studies, University of Edinburgh. These cats had no clin-
ical signs consistent with mycobacterial disease and were only included if an alternative definitive diagnosis had 
been reached. Once obtained, samples were kept at 4 °C and assayed within 12 hours.
Cats were excluded from this group for any one or more of the following: a diagnosis of stage V neoplasia (i.e. 
bone marrow involvement was confirmed), myelodysplastic disorder, exogenous retroviral (FIV/FeLV) infection 
or if they had received treatment with any immunomodulatory medicines including NSAIDs, corticosteroids or 
chemotherapeutic agents.
Cytokine and chemokine measurements. Cytokine and chemokine concentrations were measured in 
all of the samples using a commercial, feline specific, antibody-coated microsphere-based multiplex cytokine 
immunoassay shown to be able to quantify 19 cytokines contemporaneously using 25 ul of each patient’s serum 
(FCTYOMAG-20K MILLIPLEX MAP Feline Cytokine/Chemokine Magnetic Bead Panel, Premix 19 Plex kit, 
MERCK Millipore Corporation, Billerica, MA, USA).
The following cytokines were measured: sFas, Flt-3 ligand, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, 
IL-12-(p40), IL-13, IL-18, KC, MCP-1, PDGF-BB, RANTES, SCF, SDF-1, TNF-α. All samples, standards and 
quality controls were assayed in accordance with the manufacturer’s instructions. All samples were assayed in 
duplicate and mean values analysed. Overnight incubation at 4 °C and a magnetic plate washer were utilised. The 
plates were read with a multiplex plate reader and companion software. All cytokine and chemokine concentra-
tions are reported in pg/mL.
Statistical analysis. Statistical analysis was performed using commercially available statistical software 
(GraphPad Prism 7.0). Mean values of duplicate samples for each cat were used for analysis. For the purposes of 
statistical analysis, values that fell below the limit of detection of the assay were assigned a concentration of 0 pg/
mL.
Initially, to compare all mycobacteria positive samples (n = 116) to healthy control cats (n = 16), the 
D’Agostino & Pearson omnibus test was used to confirm a Gaussian distribution of the control group data for 
each of the cytokines/chemokines measured. As no reference intervals currently exist for these biomarkers in the 
cat, these were generated from the healthy control cat population to include values 1.96 standard deviations above 
and below the mean of the control group (i.e. to encompass ~95% of the healthy population) for each cytokine/
chemokine measured. The mean concentration, standard deviation and reference interval (RI) generated for each 
molecule measured are shown in Supplementary Table I.
For mycobacteria-infected cats, 95% confidence intervals around the mean were generated by 
logarithmic-transformation of the cytokine values so that the data conformed to a Gaussian distribution. On this 
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basis, a 95% confidence interval was then generated for the transformed data which was then reverse transformed 
to give the confidence intervals provided in Supplementary Table 1.
Cytokine levels were considered to be statistically significantly different between mycobacteria-infected and 
healthy control cats if there was no overlap between the RI generated from the control data and confidence inter-
vals of data generated from infected cats (shown in bold in Supplementary Table I).
A second comparison was made between mycobacteria-infected, healthy control cats and hospitalised cats. 
Confidence intervals for the cytokine levels of hospitalised cats were generated in the same way as described for 
mycobacteria-infected cats and are shown in Supplementary Table 1. Again, cytokine levels were considered to be 
significantly different between groups if there was no overlap between the RI generated from the control data and 
confidence intervals of data generated from sick cats or mycobacteria infected cats.
A sub-group analysis was conducted to compare healthy control (n = 16), M. bovis infected (n = 22), M. 
microti infected (n = 43) and NTM infected cats (n = 15) with each other. Of these four groups, only cytokine 
concentrations within the healthy control group followed a Gaussian distribution as assessed by D’Agostino & 
Pearson omnibus test. Therefore, a Kruskal-Wallis test by ranks was used to determine if differences existed 
between the groups for each cytokine measured. Where significant differences were found (defined as p < 0.05), 
each group was compared in a consecutive pairwise manner using Mann-Whitney U tests with post-hoc 
Bonferroni correction applied to accommodate for multiple comparisons. Resultantly, a value of p ≤ 0.003 
was considered statistically significant for sub-group analyses. The median, range and 95% confidence interval 
for the cytokine concentrations measured within each sub-group of mycobacteria-infected cats are shown in 
Supplementary Table II.
Results
Patient characteristics. All cats included in this study were adult cats from the UK. In total, serum/plasma 
from 116 cases of feline mycobacterial disease met the inclusion criteria for the study, and serum from 16 healthy 
control cats and six hospitalised cats was also analysed.
Within the group of cats with clinical mycobacteriosis, the infecting organism was speciated based on IGRA, 
culture and/or PCR for 80 of the 116 (69.0%) cats. Of these, 22 (27.5%) were infected with M. bovis, 43 (53.8%) 
were infected with M. microti and the remaining 15 (18.7%) infected with NTM.
For the cats hospitalised for independent reasons the final diagnoses were established as hyperthyroidism 
(n = 2), congestive heart failure due to hypertrophic cardiomyopathy, hepatic lipidosis, lysosomal storage disease, 
chronic kidney disease and diabetes mellitus.
Cytokine and chemokine concentrations. All mycobacteria-infected cats compared to healthy control 
cats. The mean/median and standard deviation/range for each cytokine concentration for each of these groups is 
shown in Supplementary Table I. Three cytokines; sFAS, IL-13 and IL-4 were found to be significantly reduced in 
the mycobacteria-infected group compared to healthy control cats (Fig. 1). By contrast, seven cytokines; GM-CSF, 
IL-2, PDGF-BB, IL-8, KC, RANTES and TNF-α were present in significantly elevated concentrations within the 
peripheral circulation of mycobacteria infected cats when compared to healthy control animals (Fig. 2).
There was no significant difference between the two groups in their circulating concentrations of Flt-3 ligand, 
IFN-γ, IL-1β, IL-12 (p40), IL-6, IL-18, SDF-1, MCP-1, or SCF.
Comparison of all mycobacteria-infected cats to hospitalised cats and controls. To begin to assess the specificity 
of changes in cytokine concentrations between feline mycobacteriosis patients and healthy controls, serum from 
six hospitalised cats was analysed and compared to both of these groups, data shown in Supplementary Table 1.
The cytokines GM-CSF, IL-2, PDGF-BB, RANTES and TNF-α were found at significantly elevated concentra-
tions, whilst IL-4 and sFAS were detected at reduced concentrations in mycobacteria infected cats compared to 
both hospitalised non mycobacteria-infected cats and healthy controls (Fig. 3).
The concentrations of IL-13 and IL-1β were found to be significantly reduced in hospitalised cats when com-
pared to both control cats and those with mycobacterial infections (Fig. 4). Whilst differences in the concentra-
tions of IL-8 and KC were observed between healthy cats and those infected with mycobacteria, there was no 
difference in the concentrations of these cytokines between cats infected with mycobacteria and cats hospitalised 
for unrelated conditions (Fig. 4).
Figure 1. Cytokines found to have significantly reduced concentrations in the peripheral blood of cats with 
mycobacterial disease compared to healthy controls. Data are shown as the median for the group with error bars 
indicting the 95% confidence interval.
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Comparison of cats infected with different mycobacterial species. Of the 116 cats enrolled in the study, 80 had 
their mycobacterial infections definitively speciated to one of three causative agents, or group of causative agents; 
M. bovis, M. microti and NTM infections. These groups were compared to one another and also against the 
healthy control group. This analysis revealed the concentration of TNF-α to be significantly increased in the M. 
bovis-infected group when compared to all other groups; while the concentration of PDGF-BB was found to be 
significantly increased in cats infected with M. microti compared to all remaining groups (Fig. 5). Concentrations 
of GM-CSF, IL-2 and Flt3-L were significantly increased in both MTBC groups (M. bovis and M. microti) when 
compared to the remaining two groups (Fig. 6).
The group of cats infected with NTM species had a significant reduction in the concentration of MCP-1 in 
comparison to the healthy controls (data not shown).
Concentrations of cytokine IL-8 were increased in all three mycobacteria-infected groups when compared to 
healthy control animals (data not shown), with the greatest increase observed in the cats with NTM infections, 
though this trend was not statistically significant (p = 0.07).
Figure 2. Cytokines found to have significantly increased concentrations in the peripheral blood of cats with 
mycobacterial disease compared to healthy controls. Data are shown as the median for the group with error bars 
indicting the 95% confidence interval.
Figure 3. Cytokines found to have significantly altered concentrations in the peripheral blood of cats with 
mycobacterial disease compared to healthy controls and/or cats hospitalised for other reasons. Data are shown 
as the median for the group with error bars indicting the 95% confidence interval.
Figure 4. Cytokines found to have significantly altered concentrations in the peripheral blood of cats with 
mycobacterial disease compared to healthy controls and/or cats hospitalised for other reasons. Statistically 
significant differences between groups were determined by Kruskal-Wallis test by ranks (P < 0.05), each 
group was compared in a consecutive pairwise manner using Mann-Whitney U tests with post-hoc Bonferroni 
correction applied to accommodate for multiple comparisons (P ≤ 0.003). Data are shown as the median for the 
group with error bars indicting the 95% confidence interval.
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Discussion
Current routine clinical methods for the diagnosis of feline mycobacterial disease, and tuberculosis in particular, 
have a number of drawbacks. Multiplex immunoassays have proven to be sensitive, specific, rapid, require very 
small sample volumes, and show a broad analytical and dynamic range66–70. The benefits of the multiplex assay 
approach used in this study include more rapid availability of results than currently achievable with culture or 
IGRA, and that this analysis requires only a small volume of serum or plasma to analyse (25 ul)66–70.
This population of cats consisted of adult cats resident in the UK; previous studies have shown that male 
cats are over-represented in the population of cats presenting with mycobacterial infections and cats are usually 
younger when they present with M. bovis compared to M. microti infections13,34. It was not possible for us to 
determine if any such bias existed within our study population as signalment data was infrequently reported to us 
by primary veterinary clinicians. The reasons for this are unclear but it may be a reflection of the predominately 
outdoor and semi-feral lifestyles of many of these cats meaning that there is limited information definitively 
known about them.
All samples used in this study were opportunistically obtained remnants collected as part of other diagnos-
tic investigations and processed by primary veterinary clinicians. This approach meant that samples could be 
sourced ethically and provides demonstrable ‘proof of concept’ that such methodology is potentially practicable 
and achievable within a clinical setting. Due to the remnant nature of samples analysed in this study, one must 
be cognisant of the possibility that post-collection processing may not have been consistent across samples e.g. 
storage temperature, which may have influence on individual findings71,72. However, it seems reasonable to pre-
sume that such adverse effects would not impact any one group of cats in this study in particular, but occur ran-
domly throughout the dataset generated and so the results obtained in this study are still (clinically) interpretable. 
Similarly, due to the opportunistic nature of sample collection, this study included two different types of sample 
media; serum and heparinised plasma. Previous work with the same commercially available multiplex assay kit 
has demonstrated strong correlation between cytokine/chemokine concentrations obtained in paired serum and 
heparinised plasma samples taken from the same cat70,73, and so again it would seem the results obtained in this 
study remain reliable and interpretable.
Figure 5. Cytokines found to have significantly altered concentrations in the peripheral blood of cats with 
mycobacterial disease due to M. bovis or M. microti, respectively, compared to healthy controls and cats infected 
with non-tuberculous mycobacterial (NTM) species. Data are shown as the median for the group with error 
bars indicting the 95% confidence interval.
Figure 6. Cytokines found to have significantly altered concentrations in the peripheral blood of cats with 
mycobacterial disease due to TB-complex infections (M. bovis or M. microti respectively), compared to healthy 
controls and cats infected with non-tuberculous mycobacterial (NTM) species. Data are shown as the median 
for the group with error bars indicting the 95% confidence interval.
www.nature.com/scientificreports/
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The inflammatory cascade induced by mycobacterial infection is complex and is poorly characterised in the 
cat. The hallmark lesion of mycobacterial infections, including TB, is the granuloma which is a compact, organ-
ised aggregate of immune cells formed as part of the host immune response to the persistent stimuli of the path-
ogen15,74–76. Upon phagocytosis, inhibition of phagosome-lysosome fusion enables the intracellular survival of 
mycobacteria within these phagocytes77. The internalised bacilli are then believed to stimulate the infected mac-
rophage to invade the local tissues78,79. The stimulation of macrophage Toll-like receptors (TLRs) by mycobacteria 
induces the production of numerous cytokines, predominantly TNF-α, which drives the recruitment of mononu-
clear cells and neutrophils from surrounding blood vessels. In particular, there is recruitment of activated T-cells 
which interact with activated macrophages and secrete IFN-γ leading to mycobacterial killing80–84. Additionally, 
each group of recruited cells also release their own assortment of cytokines and chemokines which perpetuate the 
inflammatory cascade and the formation of a stable granuloma structure81,85.
In this study, we demonstrated that changes in the concentrations of eight critically important cytokines gave 
a sensitive and specific indication of mycobacterial infection in this study population. Elevated concentrations 
of the cytokines GM-CSF, IL-2, PDGF-BB, IL-8, KC, RANTES and TNF-α in mycobacteria infected cats with 
concurrent reductions in sFAS, IL-13 and IL-4 are suggestive of a pro-inflammatory process occurring in these 
patients, which is dominated by the recruitment and maturation of monocyte-macrophage lineage cells, the 
recruitment of cytotoxic T-cells, the proliferation of fibroblasts and the suppression of humoral immunity.
Granulocyte-macrophage colony-stimulating-factor (GM-CSF) is a critically important cytokine involved 
in the innate immune response against mycobacteria, specifically via influencing macrophage and dendritic 
cell function86–92. GM-CSF deficient mice are extremely susceptible to mycobacterial disease and their mac-
rophages fail to effectively inhibit intracellular pathogen replication90. Similarly, humans with detectable titres of 
anti-GM-CSF auto-antibodies show an increased susceptibility to pulmonary tuberculosis compared to healthy 
controls, whilst GM-CSF immunotherapy can contribute to the resolution of disease due to drug-resistant M. 
tuberculosis93,94. GM-CSF activated cells, principally macrophages, go on to propagate the inflammatory cascade 
in particular via the production of TNF-α86.
GM-CSF has been shown by previous multiplex cytokine analyses to be critical in the early response and possible 
clearance of M. tuberculosis in humans and mice, so that the use of recombinant GM-CSF as an adjunctive therapy 
for TB has been posited; the findings of this study suggest that this may also be of benefit to feline patients.
TNF-α is an agonist of both nuclear factor (NF)-kB and mitogen-activated protein kinase (MAPK) which lead 
to downstream upregulation of pro-inflammatory immune functions including but not limited to; increased cell 
adhesion (e.g. giant cell formation) and macrophage apoptosis which are beneficial to the control of mycobacte-
rial infections95–97. One such downstream effect is the increased expression and secretion of chemokines includ-
ing RANTES and interleukin IL-898–100. These molecules are major drivers in the recruitment and migration of 
leukocytes towards an inflammatory focus98–100. Additionally, RANTES can combine synergistically with other 
locally secreted cytokines, such as IL-2 released from T-cells and IL-12(p40) released from pathogen-activated 
antigen-presenting cells e.g. mature dendritic cells, in order to stimulate the activation and proliferation of natural 
killer (NK) cells, which ultimately leads to a local increase in mycobactericidal activity98–100.
TNF-α, one of the most studied cytokines in the human mycobacterial response, has been repeatedly shown to 
be of significant diagnostic utility for mycobacterial infections in humans, with concentrations varying between 
TB and non-TB patients as well as being discriminatory between active and latent infections and generally being 
found to decline with successful therapy53–56. Similarly, a number of patients receiving TNF-α antagonists such 
as infliximab have been reported to contract and even die from mycobacterial infections101–103. In this study, it is 
notable that this cytokine was the only one to be uniquely indicative of infection with M. bovis. This is potentially 
due to the secretion of RD1 proteins during the course of these infections generating a more pro-inflammatory 
state in M. bovis infected cats. The possibility that cats infected with mycobacteria and with elevated TNF-α could 
have more severe or active disease and hence pose a more serious zoonotic threat to humans is one that warrants 
further investigation.
An essential step in the formation of an effective granuloma structure is fibroblast proliferation, mediated at 
least in part by the local production of PDGF-BB104. Similar to TNFα, it has recently been demonstrated that cir-
culating levels of this cytokine are elevated in human patients with active pulmonary tuberculosis, and that these 
levels decline significantly over a six month course of therapy54. However, in contrast to TNFα, within our feline 
population, PDGF-BB was only detected at significant levels in cats infected with M. microti. This may indicate a 
difference in the immune response by cats to this species of mycobacteria, which was used as the human vaccine 
strain prior to the availability of M. bovis-BCG, and may therefore be considered attenuated105. Future analysis 
and comparison of the granuloma structures of M. microti and M. bovis infected cats may show physical manifes-
tations of such differences, and may be useful to identify prognostic features of relevance to feline disease.
The Fas/Fas-ligand (FasL) system is an important molecule for immunological regulation; specifically it main-
tains T-cell homeostasis by the induction of apoptosis in order to limit T-cell expansion following antigenic stim-
ulation106,107. It has been reported that mycobacteria exploit this system in order to subvert and evade the adaptive 
immune response of an infected animal by generating an immune-privileged niche106,108. Soluble Fas (sFAS) can 
antagonise cell surface FasL by competitive inhibition and so allow continued T-cell proliferation, a phenomenon 
shown to be significant in lymphoproliferative disorders such as non-Hodgkin’s lymphoma109.
This is the first time, to our knowledge, that evidence of such an extensively conserved systemic immune 
response to these infectious agents, directly comparable to that seen in many human and animal models of myco-
bacterial disease, has been demonstrated in the cat. This suggests that the occurrence of mycobacterial infections 
in this species could act as a naturally occurring model of human disease. This capacity could be particularly sig-
nificant in overcoming the known shortcomings of murine models of mycobacterial disease, particularly as feline 
cases occur with relatively high clinical frequency and so could provide a naturally-occurring reliable source of 
study data.
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Within the variety of mycobacterial species which are known to infect cats; those belonging to the MTBC, 
and M. bovis in particular, pose the greatest risk of zoonotic spread to in-contact humans39–41. Currently the gold 
standard diagnostic test to identify these organisms which can threaten human health is mycobacterial culture; 
however, M. bovis takes a minimum of 6–8 weeks to confirm by culture and M. microti requires even longer at 
12–16 weeks9,14,42. Within the cytokines analysed in this study; Flt-3L, GM-CSF and IL-2 were all significantly 
elevated in cats with a diagnosis of infection with an MTBC organism compared to all other groups. Therefore, 
it may be possible that these cytokines in particular could be used to more rapidly identify those infections that 
pose zoonotic risk to owners and the general public, allowing for earlier intervention.
Cytokine profiling in companion animal medicine has been the subject of a number of recent studies62,64,65. 
One limitation of such studies to date is the study design to compare cytokine profiles in animals with the des-
ignated diagnosis of interest and apparently healthy animals as controls. In our investigations, we additionally 
included a small number of cats that had been hospitalised for reasons unrelated to mycobacterial disease. This 
allowed us to identify that the changes in concentration of the cytokines KC and IL-8 were not specific to myco-
bacterial infection, but rather may simply occur when cats were ill or stressed. These findings indicate that includ-
ing such a group in experimental design is and will be important for the assessment of diagnostic accuracy, 
including sensitivity and specificity, of cytokine profiling in the future. Greater accuracy would be achieved by 
expanding on our small sample size (n = 6) and also by matching the diagnoses in this group to those with similar 
aetiopathogenesis to the diagnosis of interest. For example, such a study could include cats with other infectious 
granulomatous disease such as feline infectious peritonitis (FIP), where multiplex expression profile analysis of 
serum samples have also shown elevations in RANTES and GM-CSF concentrations64.
A limitation of the study we report here is its retrospective nature; this meant that it was not possible to have 
a standardised diagnostic assessment of each cat and samples from each cat did not undergo the gold standard 
test of mycobacterial culture. The majority of cats in this study were diagnosed by IGRA which has been shown to 
have a higher sensitivity for MTBC than NTM infections, which may have introduced some bias towards MTBC 
infected individuals in our population45. Similarly, the amount of time elapsed between the time of infection, the 
infective dose received, and the time of blood sampling was not known for these cats. It is therefore possible that 
the changes seen could reflect different stages or magnitude of the feline response to mycobacteria; for example, 
MTBC infections may be diagnosed earlier in the course of infection than NTM infections and so the differences 
seen may simply reflect an early immune response. It was therefore not possible for us to generate sensitivity or 
specificity data for these cytokines nor to assess their diagnostic capacity in combination as has been achieved 
in human medicine. To further investigate the potential for cytokine profiling in feline mycobacterial disease, 
prospective recruitment of cases would allow for additional control over the time of blood sampling in relation 
to patients being presented to a veterinary surgeon. Such a study would additionally further allow changes in 
cytokine concentrations to be tracked over time, and in response to treatment. This would allow much greater 
accuracy regarding the cessation of antimicrobial therapy in these cases, which is not currently possible.
Conclusion
In this study, we demonstrate a conserved immunological response to mycobacteria by domestic cats analogous 
to that of other species. Further research into feline tuberculosis as a spontaneously occurring model of a signif-
icant human disease is urgently required. These data show that cytokine profiling has the practical and immu-
nological potential to be developed as a sensitive and specific diagnostic test for the presence of mycobacteria in 
feline infections, to readily speciate them and help inform on zoonotic risk to exposed humans. The Milliplex 
MAP Feline Cytokine Magnetic Bead multiplex assay was shown to be a practicable and reliable platform for 
these measurements and further work should focus on the prospective diagnostic utility of the findings reported 
in this study.
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